Tirzepatide has recently been FDA approved for weight loss under the brand name Zepbound, and is also the active ingredient in Mounjaro. Tirzepatide acts on multiple hormone receptors, offering a unique approach to reducing appetite, regulating blood sugar levels, and promoting weight loss.

Glucose control

Tirzepatide is a dual glucose-dependent insulinotropic peptide (GIP) and glucagon-like peptide-1 receptor agonist (GLP-1 RA). It helps to regulate blood sugar levels by stimulating insulin release and reducing glucagon secretion.

Weight management

Tirzepatide has also demonstrated significant weight loss effects in clinical trials. It has been shown to promote greater weight loss compared to other diabetes medications, making it a valuable option for individuals with type 2 diabetes who are struggling with obesity or weight management.

Cardiovascular benefits

Similar to Semaglutide, Tirzepatide has shown cardiovascular benefits in clinical studies. It has been associated with a reduced risk of major cardiovascular events in people with type 2 diabetes and established cardiovascular disease.

How Does Tirzepatide Work?

Tirzepatide, the active ingredient in Mounjaro and Zepbound (recently FDA approved for weight loss), unveils a different pathway to weight loss. Acting as a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, Tirzepatide takes a multifaceted approach to target various hormone receptors. By curbing appetite, regulating blood sugar levels, and igniting weight loss, Tirzepatide has shown to be incredibly effective. In the FDA approval process, patients at the highest dose lost over 58lb (25% of body weight) compared to 1.5% on the placebo.

Approval is done by a one time telemed appointment with a medical provider licensed in South Dakota. This can be completed with us or at your own home.

Contact for Pricing